Research progress on mechanisms and therapeutic drugs of hypoxic pulmonary hypertension / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 1281-1288, 2022.
Article
en Zh
| WPRIM
| ID: wpr-1014003
Biblioteca responsable:
WPRO
ABSTRACT
Hypoxic pulmonary hypertension ( HPH) is a complex mechanism of HPH is complex, and it has a high mortality rate cardiopulmonary disease eaused by hypoxia.The pathological of disability.Clinically the diug of treatment for HPH is unspe-cialized, mainly relying on traditional vasomotor dnrgs, inclu¬ding prostaglandin 12 receptor agonists, endothelin receptor an¬tagonists and phosphodiesterase-5 inhibitors, but their efficacy cannot be achieved.To meet the clinical need, it is of great sig¬nificance to develop targeted anti-HPH dnigs.To provide ideas for the discovery of HPH treatment drugs, the pathophysiological mechanism of HPH and the current status of dmg development are reviewed in the paper.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Pharmacological Bulletin
Año:
2022
Tipo del documento:
Article